SynthesisBasic & clinical pharmacology & toxicology2025
Adherence in the Treatment of Inflammatory Bowel Disease With Particular Focus on the Importance of the Clinical Pharmacist: A Systematic Review.
Synthesis in Basic & clinical pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Adherence in the Treatment of Inflammatory Bowel Disease With Particular Focus on the Importance of the Clinical Pharmacist: A Systematic Review.Basic & clinical pharmacology & toxicology · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prevalence of inflammatory bowel disease (IBD) is increasing. While several studies have shown that incorporating a clinical pharmacist into patient care can improve quality of life, evidence specifically addressing their role in IBD management remains limited.
objectivesThis study aimed to systematically review the evidence on treatment adherence in IBD, with a focus on the potential role of clinical pharmacist counselling to improve medication adherence.
methodsThree databases (PubMed, MEDLINE and Embase) were searched to identify relevant literature, using keywords derived from the PICO model.
resultsSeven full-text articles met the inclusion criteria. Three of these reported that pharmacist involvement had a positive effect on treatment adherence in patients with IBD. Furthermore, two studies reported that pharmacist involvement in treatment improved disease activity. Patients' perceptions of pharmacist involvement were generally positive, particularly after receiving information about pharmacist services and education. Finally, studies also indicate that pharmacists require greater knowledge of IBD to provide optimal care.
conclusionAlthough the available literature is limited, it indicates that involving clinical pharmacists in IBD treatment may have a positive impact-improving medication adherence and enhancing disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.